Condition (MeSH)
Ophthalmia, Sympathetic
ClinicalTrials.gov lists 2 trials for Ophthalmia, Sympathetic or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Ophthalmia, Sympathetic itself; the rest are tagged with a narrower condition beneath it.
When did Ophthalmia, Sympathetic trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2013 | 1 |
| 2008 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ophthalmia, Sympathetic trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 1 |
How many Ophthalmia, Sympathetic trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ophthalmia, Sympathetic trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Clearside Biomedical, Inc. | 1 |
| Novartis Pharmaceuticals | 1 |
Which serious adverse events do Ophthalmia, Sympathetic trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypokalaemia | 1 | 1 |
| Pulmonary embolism | 1 | 1 |
| Pyelonephritis | 1 | 1 |
| Tibia fracture | 1 | 1 |
| Urinary tract infection | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Ophthalmia, Sympathetic? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Enucleation, evisceration, and sympathetic ophthalmia. | Current opinion in ophthalmology | 2000 | Yes |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Sympathetic ophthalmia | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Sympathetic ophthalmia | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Sympathetic ophthalmia | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Unspecified |
| Sympathetic ophthalmia | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Sympathetic ophthalmia | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Sympathetic ophthalmia | 79098 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Sympathetic ophthalmia | 79098 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.